Table 1. Cox regression for prognosis and hepatic carcinogenesis in patients with alcoholic liver cirrhosis.
| N = 104 | P value | P value | |||
|---|---|---|---|---|---|
| Cox regression | median (min–max) | Prognosis | Hepatic carcinogenesis | ||
| (Univariate or Multivariate) | or n (%) | Univariate | Multivariate | Univariate | Multivariate |
| Age, years | 60 (30–82) | 0.827 | 0.054 | ||
| Gender | |||||
| Males | 83 (79.8) | 0.898 | 0.074 | ||
| Females | 21 (20.2) | ||||
| Gastroesophageal varices | 18 / 20 / 48 / 15 | 0.340 | 0.680 | ||
| (F0 / F1 / F2 / F3 or rupture) | |||||
| Ascites | 59 / 23 / 22 | 0.051 | 0.286 | ||
| (None / mild / moderate to severe) | |||||
| Overt hepatic encephalopathy | 5 (4.8) | 0.514 | 0.258 | ||
| Charlson comorbidity index | 4 (3–7) | 0.063 | 0.043* | 0.045* | |
| Body mass index, kg/m2 | 23.8 (15.6–40.6) | 0.011* | 0.713 | 0.028* | 0.030* |
| Skeletal muscle mass index, cm2/m2 | 43.6 (21.5–71.9) | 0.802 | 0.206 | ||
| SAT index, cm2/m2 | 34.8 (1.8–135.3) | 0.013* | 0.009* | 0.163 | |
| VAT index, cm2/m2 | 39.3 (3.3–125.0) | 0.687 | 0.032* | 0.598 | |
| TAT index, cm2/m2 | 76.1 (5.1–236.9) | 0.141 | 0.055 | ||
| Aspartate aminotransferase, U/L | 50 (15–538) | 0.023* | 0.094 | 0.145 | |
| Alanine aminotransferase, U/L | 29 (10–576) | 0.026* | 0.474 | 0.340 | |
| Albumin, g/dL | 3.1 (1.5–4.9) | 0.004* | 0.806 | 0.946 | |
| Total bilirubin, mg/dL | 1.7 (0.5–27.1) | <0.001* | 0.003* | 0.278 | |
| Gamma-glutamyl transpeptidase, U/L | 117 (15–1167) | 0.772 | 0.358 | ||
| Cholinesterase, U/L | 122 (30–359) | 0.056 | 0.747 | ||
| Prothrombin time, % | 64 (17–110) | <0.001* | 0.007* | 0.688 | |
| Fibrinogen, mg/dL | 191 (43–581) | 0.006* | 0.453 | 0.131 | |
| Ammonia, μg/dL | 95 (25–311) | 0.185 | 0.099 | ||
| Creatinine, mg/dL | 0.74 (0.36–2.95) | 0.236 | 0.591 | ||
| Blood urea nitrogen, mg/dL | 13 (3–84) | 0.350 | 0.313 | ||
| eGFR, mL/min/1.73m2 | 81.3 (14.0–159.0) | 0.542 | 0.599 | ||
| White blood cell count, x103/μL | 5.31 (39.88–2.45) | 0.061 | 0.102 | ||
| Platelet count, x104/μL | 9.3 (3.3–31.8) | 0.020* | 0.142 | 0.293 | |
| C-reactive protein, mg/dL | 0.28 (0.01–17.47) | 0.861 | 0.218 | ||
| Hemoglobin A1c, % | 5.2 (3.2–9.4) | 0.128 | 0.376 | ||
| Post definitive therapy for HCC | 4 (3.8) | 0.356 | 0.419 | ||
| Child-Pugh score | 8 (5–13) | 0.009* | 0.221 | ||
| ALBI score | -1.67 (-3.32–0.30) | <0.001* | 0.851 | ||
| 5-year incidence rate of HCC | 34.7 | - | - | ||
| 5-year survival rate | 54.0 | - | - | ||
SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; TAT, total adipose tissue; eGFR, estimated glomerular filtration rate; HCC, hepatocellular carcinoma
*:P value < 0.05.